Team:BIOSINT Mexico/pitch

From 2012e.igem.org

(Difference between revisions)
Line 156: Line 156:
Consolidating a Synthetic Biology enterprise that provides custom synthetically designed and optimized genes, recombinant proteins, and specialized biotechnological solutions in the region, would capture the existing market-share and at the same time would fuel the development of a fresh new market that currently remains underexploited.</br></br>
Consolidating a Synthetic Biology enterprise that provides custom synthetically designed and optimized genes, recombinant proteins, and specialized biotechnological solutions in the region, would capture the existing market-share and at the same time would fuel the development of a fresh new market that currently remains underexploited.</br></br>
 +
 +
<div style="text-align: center;"><img src="http://www.persoft.mx/biosint/images/Executive2.png"/></div></br>Regional Average 57.2/ Global Average 53.8/ Emerging Markets Average 51.3</br>
 +
Source: BMI 2012</br></br>
 +
 +
<div style="text-align: center;"><img src="http://www.persoft.mx/biosint/images/Executive3.png"/></div></br></br>
Kuxtal Biotech has identified the need for a company that supplies quality services with both speed and an excelling customer support. The opportunities for business development of genomic technologies in Mexico have been underrated. Kuxtal Biotech intends to get a grip on the already existing market, and develop it, by supplying quality products and services with on-time deliveries, validation, and technical assistance through all the research and project development process.
Kuxtal Biotech has identified the need for a company that supplies quality services with both speed and an excelling customer support. The opportunities for business development of genomic technologies in Mexico have been underrated. Kuxtal Biotech intends to get a grip on the already existing market, and develop it, by supplying quality products and services with on-time deliveries, validation, and technical assistance through all the research and project development process.

Revision as of 00:59, 28 October 2012

Kuxtal

WHAT I CANNOT CREATE, I DO NOT UNDERSTAND RICHARD FEYNMAN’S
Mexico is located in the “Ring of Fire”.
It is one of the earth’s most violent earthquake and volcano zones.

Project Summary

Elevator pitch video

Business model.

Executive summary

Continuous advances in biological science have led to the broadening of commercially available molecular biology reagents and equipment, from where many techniques, applications, products and services for both industry and laboratory have developed.

Latin America is a region with great potential in market development and expansion.



Consolidating a Synthetic Biology enterprise that provides custom synthetically designed and optimized genes, recombinant proteins, and specialized biotechnological solutions in the region, would capture the existing market-share and at the same time would fuel the development of a fresh new market that currently remains underexploited.


Regional Average 57.2/ Global Average 53.8/ Emerging Markets Average 51.3
Source: BMI 2012



Kuxtal Biotech has identified the need for a company that supplies quality services with both speed and an excelling customer support. The opportunities for business development of genomic technologies in Mexico have been underrated. Kuxtal Biotech intends to get a grip on the already existing market, and develop it, by supplying quality products and services with on-time deliveries, validation, and technical assistance through all the research and project development process.